Press "Enter" to skip to content

WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer – GlobeNewswire

admin 0

WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer  GlobeNewswire

BALTIMORE and PHILADELPHIA, June 25, 2019 (GLOBE NEWSWIRE) — WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating …

“lung cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *